Research Paper Volume 16, Issue 6 pp 4948—4964

Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging

class="figure-viewer-img"

Figure 5. Administration of MB during aging does not alter trabecular bone morphology of the axial skeleton. Eighteen-months old female C57BL/6J were divided into two groups. One group was exposed to regular drinking water and the other to 250 μM MB-containing water. Mice were sacrificed at basal (18 months), 24, or 30 months of age. An additional group of female mice at 5 months of age, served as young controls. Bones were dissected and subjected to micro-CT. Trabecular bone parameters of the L5 vertebra were taken at the vertebral body including, (A) BV/TV-bone volume/total volume, (B) BMD-bone mineral density, (C) Tb.Th-trabecular thickness, and (D) Tb.N-trabecular number. 5 months-old females n = 9, 18 months-old females n = 10, 24 months-old females n = 7, 30 months-old females n = 6, 24 months-old MB-treated females n = 8, 30 months-old MB-treated females n = 8. Data tested by multivariate ANOVA presented as mean ± SEM. Significance accepted at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).